ArticlePDF Available

A Brief Review on Liver Cirrhosis: Epidemiology, Etiology, Pathophysiology, Symptoms, Diagnosis and Its Management

Authors:

Abstract and Figures

Cirrhosis is characterized by the formation of regenerative nodules in liver parenchyma surrounded by fibrous septa due to chronic liver injury. Cirrhosis occurs due to necrosis of liver cells followed by fibrosis and nodule formation. The liver structure becomes abnormal and interferes with liver blood flow and function and leads to portal hypertension and impaired hepatocytes function. Chronic liver diseases represent a significant health problem across the globe with liver cirrhosis. The exact prevalence of cirrhosis worldwide is still unknown as the clinical spectrum ranges from indolent, asymptomatic to complete hepatic decompensation. Diagnosis of cirrhosis includes serological test, histological test, transientelastography and radio techniques like ultrasonography, computerised tomography scan and magnetic resonance imaging. Ursodeoxycholic acid is used for treatment of primary biliary cirrhosis. For treatment of autoimmune hepatitis prednisone and azathioprine are used. For hepatitis B and C treatment interferon and antiviral agents are used. For treatment of hemochromatosis phlebotomy is used. For treatment of wilson disease, trientine and zinc are used. Liver transplantation is main curative option for treatment of liver cirrhosis, but it possesses significant risk to the patient.
Content may be subject to copyright.
Inventi Rapid: Molecular Pharmacology Vol. 2014, Issue 2
[ISSN 0976-3856]
2014 pmp 277, CCC: $10 © Inventi Journals (P) Ltd
Published on Web 20/03/2014, www.inventi.in
REVIEW ARTICLE
INTRODUCTION
Liver fibrosis or scaring of liver is a complex, dynamic
change in normal wound healing response to different
fibrogenic stimuli leading to activation and trans
differentiation of hepatic stellate cells to myofibroblasts
which leads to excessive synthesis and deposition of
extracellular matrix components like collagen (type I and
type III) accompanied by distortion of normal hepatic
vasculature, hepatocyte dysfunction, irreversible liver
damage, complications and result in death. [1] Cirrhosis
occurs due to the necrosis of liver cells followed by fibrosis
and nodule formation. Impairment in liver function and
structure leads to impaired liver blood flow and function.
This derangement produces the clinical features of portal
hypertension. Cirrhosis represents the common pathway
for chronic liver diseases. In 1826, the term cirrhosis was
introduced by Laennec. It is derived from the Greek term
scirrhus which refers to the orange or tawny surface of the
liver. Cirrhosis is defined as a diffuse hepatic process
characterized by fibrosis and the conversion of normal liver
architecture into structurally abnormal nodules. The
progression of liver injury to cirrhosis may occur over
weeks to years. Patients with hepatitis C may have chronic
hepatitis for as long as 40 years before progressing to
cirrhosis. Many forms of liver injury are marked by fibrosis,
which is defined as an excess deposition of the components
of the extracellular matrix (collagens, glycoproteins and
proteoglycans) within the liver. This response to liver
injury is potentially reversible while in most patients,
cirrhosis is not a reversible process. In addition to fibrosis,
the complications of cirrhosis include portal hypertension,
ascites, hepatorenal syndrome and hepatic encephalopathy.
A poor correlation exists between histologic findings of
cirrhosis and the clinical picture. Some patients with
cirrhosis are completely asymptomatic and have a
reasonably normal life expectancy while some individuals
1Aksharpreet Institute of Pharmacy, Adi Shankaracharya Shikshan Vikas
Sankul, Jamnagar - Okha State Highway, Lakhabaval Road, Jamnagar-
361006, Gujarat, India.
E-mail: manojsuva_0211@yahoo.co.in
*Corresponding author
have severe symptoms of end-stage liver disease and
limited chance for survival. Common signs and symptoms
may arise from decreased hepatic synthetic function
(coagulopathy), decreased detoxification capabilities of the
liver (hepatic encephalopathy) or portal hypertension
(variceal bleeding). [2]
EPIDEMIOLOGY
In the United States, chronic liver disease and cirrhosis
result in about 35,000 deaths each year. In the United
States, cirrhosis is the 9th leading cause of death and
account for 1.2% of all US deaths. Fulminant hepatic failure
(FHF) accounts for 2000 additional deaths every year.
Causes of FHF includes viral hepatitis (Hepatitis A and B),
drugs (Acetaminophen), toxins like Amanita phalloides,
autoimmune hepatitis and Wilson disease. Patients with
the FHF have a 50-80% mortality rate unless liver
transplantation. [2] Different causes of cirrhosis are shown
in Table 1.
PATHOPHYSIOLOGY
The liver plays an important role in synthesis of proteins
like albumin, clotting factors, complement factors and
detoxification and storage of vitamin A. It participates in
the metabolism of lipids and carbohydrates. Cirrhosis is
often followed by hepatitis and steatosis (fatty liver)
independent of the cause. If the cause is resolved at this
stage, the changes are completely reversible. In cirrhosis,
scar tissue development replaces normal parenchyma and
blocks the portal flow of blood to organ and affects the
normal function. Research shows the important role of the
stellate cell in the development of cirrhosis which generally
stores vitamin A. Hepatic parenchyma damage due to the
inflammation, activate stellate cell and it increases fibrosis
and obstructs the blood flow in the circulation. The
formation of fibrous tissue bands separate hepatocyte
nodules which replace the entire liver architecture.
Chronic injury to the liver results in inflammation, necrosis
and subsequently fibrosis as shown in Figure 1.
Fibrosis is initiated by activation of the stellate cells and
Kupffer cells, damaged hepatocytes and activated platelets
are also involved. Stellate cells are activated by various
A Brief Review on Liver Cirrhosis: Epidemiology, Etiology,
Pathophysiology, Symptoms, Diagnosis and Its
Management
Manoj A Suva1*
Abstract:
Cirrhosis is characterized by the formation of regenerative nodules in liver parenchyma surrounded by fibrous septa
due to chronic liver injury.
Cirrhosis occurs due to necrosis of liver cells followed by fibrosis and nodule formation. The liver
structure
becomes abnormal and interferes with liver blood flow and function and leads to portal hypertension and impaired
hepatocytes function. Chronic liver diseases represent a significant health problem across the globe with
liver cirrhosis. The
exact prevalence
of cirrhosis worldwide is still unknown as the clinical spectrum ranges from indolent, asymptomatic to
complete hepatic decompensation. Diagnosis of cirrhosis includes
serological test, histological test, transientelastography and
radio techniques like ul
trasonography, computerised tomography scan and magnetic resonance imaging. Ursodeoxycholic acid
is used for treatment of primary biliary cirrhosis. For treatment of autoimmune hepatitis prednisone and azathioprine are used.
For hepatitis B and C treatment
interferon and antiviral agents are used. For treatment of hemochromatosis phlebotomy is used.
For treatment of wilson disease, trientine and zinc are used. Liver transplantation is main curative option for treatment of liver
cirrhosis, but it possesses significant risk to the patient.
1
Inventi Rapid: Molecular Pharmacology Vol. 2014, Issue 2
[ISSN 0976-3856]
2014 pmp 277, CCC: $10 © Inventi Journals (P) Ltd
Published on Web 20/03/2014, www.inventi.in
REVIEW ARTICLE
cytokines and their receptors, reactive oxygen
intermediates, autocrine signals and paracrine signals. In
the early stage of activation, the swollen stellate cells loses
retinoids with up regulation of receptors for fibrogenic and
proliferative cytokines like transforming growth factor β1
(TGF-β1) (potent fibrogenic mediator) and platelet derived
growth factor (PDGF). Inflammatory cells causes fibrosis
due to cytokine secretion. Collagens (type I and III) and
fibronectin replaces the normal matrix in the space of
Disse. Sub endothelial fibrosis leads to loss of the
endothelial function and impairs liver function.
Collagenases (matrix metalloproteinases) are able to
degrade collagen but inhibited by tissue inhibitors of
metalloproteinases (TIMPs) which level is increased in
liver fibrosis. In initial stage, liver fibrosis is reversible
when the inflammation is reduced by either suppressing or
eliminating viruses. The pathologic features of cirrhosis
includes regenerating nodules separated by fibrous septa
and loss of the normal lobular architecture within the
nodules which leads to decreased blood flow throughout
the liver. Spleen congestion leads to hypersplenism and
increased sequestration of platelets as shown in Figure 2. [4-
6] Two types of cirrhosis are described based on the
underlying cause (a) Micro nodular cirrhosis in which
regenerating nodules size is about less than 3 mm and the
involvement of entire liver and often caused by alcohol
induced damage or biliary tract disease. (b) Macro nodular
cirrhosis in which the variable size nodules are formed and
normal acini is seen within the larger nodules and it is
often associated with chronic viral hepatitis. [3]
Macroscopically, in the initial stage the liver enlarged
and as disease progresses it becomes smaller. Liver surface
becomes irregular with firm consistency and the color is
yellow if it associates with steatosis. There are three
macroscopic types depending on the size of the nodules:
micro nodular, macro nodular and mixed cirrhosis. In
micro nodular form (Laennec's cirrhosis or portal
cirrhosis) regenerating nodules size is less than 3 mm. In
Table 1: Etiology
Autoimmune
Autoimmune Hepatitis
Viral/infectious
a. Hepatitis B
b. Hepatitis C
c. Schistosomiasis
Metabolic
a. Alcohol
b. Toxins, medications
c. Hereditary hemochromatosis
d. Wilson’s disease
e. Non alcoholic steatohepatitis
f. Insulin resistance
Cholestatic
a. Primary biliary cirrhosis
b. Primarysclerosing cholangitis
c. Biliary atresia
d. Secondary biliary cirrhosis
Vascular
a. Right heart failure
b. Budd–Chiari syndrome
c. Alpha-1-antitrypsin deficiency
d. Sarcoidosis
e. Cystic fibrosis
Activation of the stellate cell is followed by proliferation of fibroblasts and
the deposition of collagen
Figure 1:
Pathogenesis of fibrosis [3]
Figure 2:
Pathology of cirrhosis
2
Inventi Rapid: Molecular Pharmacology Vol. 2014, Issue 2
[ISSN 0976-3856]
2014 pmp 277, CCC: $10 © Inventi Journals (P) Ltd
Published on Web 20/03/2014, www.inventi.in
REVIEW ARTICLE
macro nodular cirrhosis (post-necrotic cirrhosis), the
nodules size is larger than 3 mm. The mixed cirrhosis
consists of nodules with different sizes. Cirrhosis is defined
by its pathological features: (a) the presence of
regenerating nodules of hepatocytes and (b) the presence
of fibrosis or the deposition of connective tissue between
these nodules. The pattern of fibrosis depends upon the
underlying causes. The fibrosis lead to normal tissues
destruction in the liver including sinusoids, the space of
Disse and vascular structures which lead to alteration in
resistance to blood flow in the liver and portal
hypertension. [7] Different entities injured the liver in
different ways causing specific abnormalities. (In chronic
hepatitis B- infiltration of the liver parenchyma with
lymphocytes is seen). [7] In cardiac cirrhosis erythrocytes
are present and fibrosis in the tissue surrounding the
hepatic veins is seen. [8] In primary biliary cirrhosis fibrosis
is seen around the bile duct. The granulomas are also
present and in alcoholic cirrhosis neutrophils infiltrates in
liver. [7, 9]
SYMPTOMS AND COMPLICATIONS OF CIRRHOSIS
In early stage of cirrhosis there are usually no symptoms.
Progressive condition it causes symptoms like Loss of
appetite, Tiredness, Nausea, Weight loss, abdominal pain,
Spider-like blood vessels, severe itching and various
complications are as follows:
1. Impaired metabolic and endocrine functions: Jaundice
2. Splenomegaly due to portal hypertension.
3. Haematological derangements such as
thrombocytopenia.
4. Gastrointestinal varices.
5. Ascites a severe complication due to portal
hypertension.
6. Spontaneous bacterial peritonitis.
7. Hepatocelluar carcinoma.
8. Hepatic encephalopathy.
9. Hyponatremia.
10.Hepatorenal syndrome.
11.Spider angiomata due to decreased oestradiol
degradation in liver. [10]
DIAGNOSIS [3, 10-12]
Serological Test
Aspartate aminotransferase (AST), Alanine transaminase
(ALT), Alkaline phosphatase (ALP), bilirubin, prothrombin
time, Gamma-glutamyl transpeptidase, albumin,
immunoglobulins mainly IgG, creatinine level, sodium level,
Low sodium indicates severe liver disease due to excessive
diuretic therapy or defective free water clearance. Albumin
level decreases below 28 g/l, serum creatinine elevated
concentration increased above 130 μmol/l and the
prothrombin time is prolonged.
Histological Test
Liver biopsy is considered as gold standard for diagnosis
and sequential histological grading of fibrosis and to
confirm the type and severity of liver disease. Stains are
required for copper and iron measurement to confirm
diagnosis of Wilson’s disease or iron overload and
immunocytochemical stains detects viruses, bile ducts and
angiogenic structures.
Radio Techniques
1. Ultrasound Examination
To detect changes in size, shape of the liver and to detect
hepatocellular carcinoma. Fatty change and fibrosis
produces high level of echogenicity. In cirrhosis, there may
be distortion of the arterial vascular architecture and
marginal nodularity of the liver surface. The patency of the
portal and hepatic veins are evaluated. Elastography is
used for diagnosis and follow up monitoring to avoid liver
biopsy.
2. Computerized Tomography Scan (CT Scan)
Arterial phase contrast enhanced scans are important in
the detection of hepatocellular carcinoma. Figure 3 shows
hepatosplenomegaly and collateral vessels enlargement
Figure 3:
Irregular lobulated liver
Figure 4:
Cirrhosis with a patent portal vein and no space occupying
lesion
3
Inventi Rapid: Molecular Pharmacology Vol. 2014, Issue 2
[ISSN 0976-3856]
2014 pmp 277, CCC: $10 © Inventi Journals (P) Ltd
Published on Web 20/03/2014, www.inventi.in
REVIEW ARTICLE
below the anterior abdominal wall (with arrows) due to
portal hypertension and Figure 4 shows dilated collaterals
in liver disease.
3. Endoscopy
For detection and treatment of portal hypertensive
gastropathy and varices.
4. Magnetic Resonance Imaging (MRI) Scan
For diagnosis of benign tumours (haemangiomas).
Magnetic resonance angiography demonstrates the
vascular anatomy and Magnetic resonance
cholangiography shows the biliary tree.
Transient Elastography
Scoring systems in cirrhosis is shown in Table 2.
MANAGEMENT OF CIRRHOSIS
Nutrition and Exercise
Many patients complain of anorexia, which may be due to
direct compression of ascites on the gastrointestinal tract.
Patients should receive adequate calories and protein in
diets. In 2010, American Association for the Study of Liver
Diseases and the American College of Gastroenterology
suggested guidelines for alcoholic liver disease and
recommend aggressive treatment of protein calorie
malnutrition in alcoholic cirrhosis patients. Multiple
feedings per day, Regular exercise including walking and
swimming to prevent inactivity and muscle wasting.
Debilitated patients get benefit from formal exercise
program supervised by a physician. [13] Specific therapies
are needed in liver diseases to prevent or treatment of the
development of cirrhosis. Prednisone and azathioprine
used for autoimmune hepatitis, phlebotomy used for
hemochromatosis, interferon and other antiviral agents
used for hepatitis B and C, ursodeoxycholic acid used for
primary biliary cirrhosis and trientine and zinc used for
Wilson disease. These therapies become less effective if
chronic liver disease evolves into cirrhosis. Once cirrhosis
develops, treatment is aimed at the management of
complications like variceal bleeding, ascites and hepatic
encephalopathy. Zinc deficiency commonly is observed in
patients with cirrhosis. Treatment with zinc sulfate at 220
mg orally twice daily may improve dysgeusia, muscle
cramps and as a adjunctive therapy for hepatic
encephalopathy. Pruritus is seen in cholestatic liver
diseases (primary biliary cirrhosis) and noncholestatic
chronic liver diseases (hepatitis C). Cholestyramine is used
for the treatment of pruritus in liver disease but care
should be taken to avoid co administration of
Cholestyramine with any other medication to avoid
impairment in gastro-intestinal absorption. Other drugs for
treatment of pruritus include antihistamines
(diphenhydramine, hydroxyzine), ursodeoxycholic acid,
ammonium lactate skin cream, doxepin and rifampin and
Naltrexone (an opioid antagonist). Patients with severe
pruritus may require ultraviolet light therapy or
plasmapheresis. Some patients with chronic cholestasis or
primary biliary cirrhosis and patients receiving
corticosteroids for autoimmune hepatitis require calcium
and vitamin D supplementation or use of
aminobisphosphonate (alendronate sodium).
Vaccination
Patients with chronic liver disease should receive
vaccination to protect against hepatitis A and as a
protective measure, vaccination against influenza and
pneumococci.
Analgesics
The use of analgesics in patients with cirrhosis can be
problematic. Most hepatologists permits the use of
acetaminophen doses of up to 2000 mg/day in patients
with cirrhosis. NSAID use in patients with cirrhosis may
cause gastrointestinal bleeding. Patients with cirrhosis are
at risk for NSAID induced renal insufficiency because of
prostaglandin inhibition and impairment in renal blood
flow. Opiate analgesics must be used with caution in
Table 2: Scoring Systems in Cirrhosis [3]
(I) Modified Child’s–Pugh Classification
Score
1
2
3
Ascites
None
Mild
Moderate/severe
Encephalopathy
None
Mild
Marked
Bilirubin (μmol/L)
< 34
34–50
> 50
Albumin (g/L)
> 35
28–35
< 28
Prothrombin time
(seconds over normal)
< 4
4–6
> 6
Add Above Scores for Your Patient for Survival Figures Below
Grade (scores)
% Survival
1 year
5 years
10 years
Child’s A (< 7)
82
45
25
Child’s B (7–9)
62
20
7
Child’s C (10+)
42
20
0
(II) Model of End Stage Liver Disease (MELD)
3.8 * LN bilirubin in (mg/dL) + 9.6 * LN creatinine in (mg/dL) + 11.2 * LN (INR) + 6.4
LN- Natural logarithm, INR- International normalized ratio, MELD scores (with no complications): 1 year survival 97% (score<10), 70% (score 30-40)
4
Inventi Rapid: Molecular Pharmacology Vol. 2014, Issue 2
[ISSN 0976-3856]
2014 pmp 277, CCC: $10 © Inventi Journals (P) Ltd
Published on Web 20/03/2014, www.inventi.in
REVIEW ARTICLE
patients with hepatic encephalopathy otherwise it may
worsen underlying mental function.
Drug Hepatotoxicity in the Patient with Cirrhosis
Medications associated with drug-induced liver disease
include NSAIDs, Isoniazid, Valproic acid, Erythromycin,
Amoxicillin/clavulanate, Ketoconazole, Chlorpromazine
and Ezetimibe. Statins are frequently associated with mild
elevations of alanine aminotransferase level and should be
used safely in patients with chronic liver disease.
Other Drugs
An amino glycoside antibiotic causes nephrotoxicity in
patients with cirrhosis and should be avoided. Low dose
estrogens and progesterone appear to be safe in the setting
of liver disease. [2]
Liver Transplantation
Liver transplantation has emerged as an important strategy
in the management of patients with cirrhosis. Patients
should be referred for consideration for liver
transplantation after the first signs of hepatic
decompensation. Advances in surgical technique, organ
preservation and immunosuppression have improved the
postoperative survival. In the early 1980s, the percentage
of patients surviving 1 year and 5 years after liver
transplant were 70% and 15% respectively. Now, patients
with 1-year survival rate are about 85-90% and a 5-year
survival rate of higher than 70%. Quality of life after liver
transplant is good or excellent in most cases. [2]
CONCLUSION
Cirrhosis represents the common histologic pathway for a
variety of chronic liver diseases. The damage to
hepatocytes causes impairment in liver functions. Cirrhosis
is mainly diagnosed by liver biopsy and other serological
laboratory test and radio techniques. Prednisone and
azathioprine used for autoimmune hepatitis, interferon and
other antiviral agents used for hepatitis B and C,
phlebotomy used for hemochromatosis, ursodeoxycholic
acid used for primary biliary cirrhosis and trientine and
zinc used for Wilson disease and liver transplantation.
REFERENCES AND NOTES
1. Harshmohan. The liver, biliary tract and exocrine pancreas.
Text book of pathology. 4th Edition. Jaypee Brothers Medical
Publishers (P) Ltd, New Delhi, 569-630, 2002.
2. Wolf D C, Katz J. Cirrhosis [Online]. Available from: URL:http:
//emedicine.medscape.com/article/185856-overview, 2013.
3. Kumar P, Clark M. Chapter 7: Liver, biliary tract and pancreatic
disease. Kumar & Clark’s Clinical Medicine. 7th Edition. 2009,
Elsevier Limited, Spain, 345-47, 2009.
4. McPhee S J, Gary D. Chapter 14: Liver Disease.
Pathophysiology of disease: an introduction to clinical
medicine 6th edition. McGraw-Hill Medical, New York, 2010.
5. Iredale J P. Cirrhosis: new research provides a basis for rational
and targeted treatments. BMJ, 327(7407)143–7, 2003.
6. Puche J E, Saiman Y, Friedman S L. Hepatic stellate cells and
liver fibrosis. Comprehensive Physiology, 3(4):1473–92, 2013.
7. David B, Rippe R A. Pathogenesis of Hepatic Fibrosis. Tadataka
Yamada. Textbook of Gastroenterology. 4th Edition. Lippincott
Williams & Wilkins, Philadelphia, 2003.
8. Giallourakis C C, Rosenberg P M, Friedman L S. The liver in
heart failure. Clin Liver Dis 6 (4):947–67, 2002.
9. Heathcote E J. Primary biliary cirrhosis: historical
perspective. Clin Liver Dis, 7(4):735-40, 2003.
10. Cameron G R, Thomas J C, Karunarathe W A E. The
pathogenesis of liver injury in carbon tetrachloride and
thioacetamide poisoning. J Path Bact, 41:297-300, 1936.
11. Grant A, Neuberger J. Guidelines on the use of liver biopsy in
clinical practice. Gut, 45(4):1–11, 1999.
12. Udell J A, Wang C S, Tinmouth J, FitzGerald J M, Ayas N T, Simel
D L. Does this patient with liver disease have cirrhosis? Journal
of the American Medical Association, 307(8):832–42, 2012.
13. O'Shea R S, Dasarathy S, McCullough A J. Alcoholic liver
disease. Am J Gastroenterol, 105(1):14-32, 2010.
Cite this article as: Manoj A Suva. A Brief Review on
Liver Cirrhosis: Epidemiology, Etiology,
Pathophysiology, Symptoms, Diagnosis and Its
Management. Inventi Rapid: Molecular Pharmacology,
2014(2): 1-5, 2014.
5

Supplementary resource (1)

... The impaired blood flow in the portal vein results in portal hypertension, which is considered the main driver of the clinical manifestations associated with liver cirrhosis. The disease may eventually progress to liver failure and other serious complications such as HCC and hepatic encephalopathy [136,137]. ...
... The gold standard diagnostic test for liver cirrhosis is histopathological examination of liver biopsy [134,136]. However, this test is only used for confirmatory purposes to determine the cirrhosis cause and define its grade. ...
... In addition, the cost of these radiological methods might not be affordable by all patients. Added to that is the high cost and availability of the necessary machines [134,136,140]. In clinical laboratory, identifying patients with liver cirrhosis is usually based on evaluating the serum levels of liver transaminases and defining the blood platelets count. ...
Article
Chronic liver diseases (CLDs) are a major public health problem. Despite the progress achieved in fighting against viral hepatitis, the emergence of non-alcoholic fatty liver disease might pose a serious challenge to the public's health in the coming decades. Medical management of CLDs represents a substantial burden on the public health infrastructures. The health care cost of these diseases is an additional burden that weighs heavily on the economies of developing countries. Effective management of CLDs requires the adoption of reliable and cost-effective screening and diagnosing methods to ensure early detection and accurate clinical assessment of these diseases. Vibrational spectroscopies have emerged as universal analytical methods with promising applications in various industrial and biomedical fields. These revolutionary analytical techniques rely on analyzing the interaction between a light beam and the test sample to generate a spectral fingerprint. This latter is defined by the analyte's chemical structure and the molecular vibrations of its functional groups. Raman spectroscopy and surface-enhanced Raman spectroscopy have been used in combination with various chemometric tests to diagnose a wide range of malignant, metabolic and infectious diseases. The aim of the current review is to cast light on the use of these optical sensing methods in the diagnosis of CLDs. The vast majority of research works that investigated the potential application of these spectroscopic techniques in screening and detecting CLDs were discussed here. The advantages and limitations of these modern analytical methods, as compared with the routine and gold standard diagnostic approaches, were also reviewed in details.
... Cirrhosis at its early stages shows no symptoms, but as the condition progresses it causes symptoms such as tiredness, stomach ache, appetite loss, nausea, telangiectasia, weight loss, and severe itching. 22 Clinical symptoms like pruritus and fatigue are most common. The likelihood of progression to cirrhosis is higher at the onset of pruritus and fatigue in patients. ...
... In liver fibrosis, the level of metalloproteinases increases which inhibits collagenases, so the collagen deposited in the space of Disse is not degraded and keeps accumulating, leading to liver stiffness and other complications. 22 ...
... Liver cirrhosis, often resulting from prolonged HBV infection, is a leading risk factor for HCC (Chuang et al., 2022). The liver's role in metabolism and detoxification makes HBV-related liver damage particularly severe (Suva, 2014). Prevalence rates vary significantly worldwide, from less than 1% in the United States to 20-30% in Pacific Island nations (Hwang et al., 2011). ...
... Other causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson's disease, insulin resistance, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced hepatic cirrhosis, and right-sided chronic heart failure. Cryptogenic cirrhosis is defined as cirrhosis whose etiology is unclear (Sharma & John, 2022;Suva, 2014). ...
Article
Full-text available
Hepatic cirrhosis is characterized by fibrosis and formation of liver nodules caused by chronic injury, causing changes in the normal lobular organization of the heart. Hepatic cirrhosis can occur in all genders and about two-thirds occurs in men and one part in women. Diabetic patients can experience insulin resistance, which can be the basis for the development of complications into liver cirrhosis. This case study describes a 55 year old male patient who was diagnosed with hepatic cirrhosis with diabetes mellitus and discussed the course of the disease to the therapy given to the patient. A 55 year old male patient came with complaints of shortness of breath that had been felt for 3 months before entering the hospital. Based on the history, physical examination and search, the patient was diagnosed with liver cirrhosis, multiple liver nodules, type 2 diabetes mellitus and pulmonary tuberculosis. Hepatic cirrhosis can be caused by various diseases, one of which is diabetes mellitus. Diabetes can progress to nonalcoholic fatty liver disease and eventually to cirrhosis and hepatocellular carcinoma. Insulin resistance syndrome is the main factor that can cause cirrhosis in diabetes patients. Early diagnosis, resistance and control of risk factors as well as appropriate treatment also play an important role in reducing the damage to the prognosis of patients with hepatic cirrhosis due to diabetes mellitus.
... Thus, cirrhosis can be interpreted as a diffuse hepatic process characterized by fibrosis and conversion of liver structures to abnormal nodule structures. The condition of fibrosis is reversible; however, if a patient reaches the cirrhosis stage, it is irreversible (A Suva, 2014). Kiver cirrhosis can be divided into two, namely compensated and decompensated. ...
... Magnetic Resonance Imaging (MRI) has shown effective in diagnosis of benign tumours, vascular anatomy, biliary tree and hepatic iron and fat content in hemochromatosis. [19] The scaring of liver can estimate with some reliability by Elastography. Liver biopsy considered as gold standard for diagnosis and sequential histological grading of fibrosis. ...
... As symptoms are variable, medical examination most often focuses on the skin stigmata of liver disease and portal hypertension. Diagnosis of cirrhosis includes serological test, histological test, transient elastography, and radio techniques such as ultrasonography, computerized tomography scan, and magnetic resonance imaging (Suva 2014). Laboratory tests play an important role in the diagnosis and evaluation of patients' conditions and their results mainly show increased prothrombin time, increased bilirubin, increased albumin, and low thrombocyte count (Mahl and O'Grady 2014). ...
Chapter
Alcohol is one of the main causes of liver disease, as it is in the liver that alcohol is broken down. Excessive alcohol consumption is therefore considered a significant risk factor for liver cirrhosis. The risk increases depending on the amount and total duration of alcohol consumption, with daily heavy drinkers being most at risk. Alcohol is estimated to be responsible for approximately 50% of all liver cirrhosis worldwide. Patients diagnosed with alcohol-related cirrhosis have poorer health outcomes and higher mortality than those with non-alcohol-related cirrhosis. This indicates that alcohol-related cirrhosis represents a huge health burden. The first prerequisite for the successful treatment of alcohol-related cirrhosis, including the treatment of its complications, is complete abstinence. The co-existence of alcohol-related liver disease and alcohol use disorder in patients requires multidisciplinary care. With regard to cirrhosis, reducing alcohol consumption should be seen as an important health policy objective.
... These scars block the portal flow of blood to organs. Some etiologies are viral/infectious, metabolic disorders, cholestatic, and vascular problem [1]. Chronic liver disease causes 2 million deaths per year and liver cirrhosis is the 11th leading cause of death in the world [2]. ...
Article
Full-text available
Liver cirrhosis is caused by necrosis of liver cells leading to fibrosis and nodule formation. Structural abnormalities of the liver causing impaired hepatocyte function and portal hypertension. Hepatic hydrothorax is a less common pulmonary complication of portal hypertension. We present a 47 years old man with liver cirrhosis and recurrent massive pleural effusion. Diagnosis can be challenging because it can be associated with pulmonary or systemic disorders. Pleural fluid analysis is necessary to differentiate transudate or exudate as the cause of pleural effusion. Thoracentesis is done to reduce the complaints experienced by the patient.
Article
Full-text available
Background: Chronic liver disease and cirrhosis contribute significantly to global mortality, with limited improvements despite medical advancements. This study aims to evaluate acute decompensation of liver cirrhosis characteristics, etiology, and survival outcomes in Oman. In addition, we examined the accuracy of prognostic scores in predicting mortality at 28 and 90 days. Methods: We conducted a retrospective analysis of 173 adult patients with acute decompensation of liver cirrhosis at Sultan Qaboos University Hospital in Oman. We collected demographic, clinical, and biochemical data, including etiology, prognostic scores (CTP, MELD-Na, CLIF-C), and health outcomes. Results: Alcohol (29.5%), hepatitis C (27.75%), and hepatitis B (26.74%) were the predominant causes of liver cirrhosis in our cohort. Hepatic encephalopathy, mechanical ventilation, and admission to the intensive care unit were strongly associated with an increased mortality rate. The 1-year readmission rate stood at 42.2%. Liver transplantation was performed in 4.1% of cases. The overall mortality rate was approximately 40% during the follow-up period, and the cumulative 28-days and 90-days mortality rates were 20.8% and 25.4%, respectively. Prognostic scores (CTP, MELD-Na, CLIF-C) effectively predicted 28- and 90-day mortality, with CLIF-C demonstrating superior performance (AUROC 0.8694 ± 0.0302 for 28-day mortality and AUROC 0.8382 ± 0.0359 for 90-day mortality). Conclusion: Alcohol and viral hepatitis are the leading causes of liver cirrhosis in our study. Hepatic encephalopathy is a significant predictor of poor outcomes. Prognostic scores (CTP, MELD-Na, CLIF-C) have valuable predictive abilities for short-term mortality. These findings highlight the importance of public strategies to reduce alcohol consumption and the need for the comprehensive management of liver cirrhosis in Oman. Early diagnosis and intervention can improve clinical outcomes and support the establishment of a national organ transplantation program to address the healthcare challenge effectively.
Thesis
Full-text available
This study aimed at: I. Evaluation of the safety and efficacy of nitazoxanide in preventing the recurrence of hepatic encephalopathy. II. Investigation of the impact of nitazoxanide on patient-related quality of life.
Article
Full-text available
These recommendations provide a data-supported approach. They are based on the following: (i) a formal review and analysis of the recently published world literature on the topic (Medline search); (ii) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines (1); (iii) guideline policies, including the American Association for the Study of Liver Diseases (AASLD) Policy on the development and use of practice guidelines and the AGA Policy Statement on Guidelines (2); and (iv) the experience of the authors in the specified topic. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to the standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. To more fully characterize the quality of evidence supporting the recommendations, the Practice Guideline Committee of the AASLD requires a Class (reflecting the benefit vs. risk) and Level (assessing the strength or certainty) of Evidence to be assigned and reported with each recommendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Practice Guidelines) (3,4).
Article
>Hepatic stellate cells are resident perisinusoidal cells distributed throughout the liver, with a remarkable range of functions in normal and injured liver. Derived embryologically from septum transversum mesenchyme, their precursors include submesothelial cells that invade the liver parenchyma from the hepatic capsule. In normal adult liver, their most characteristic feature is the presence of cytoplasmic perinuclear droplets that are laden with retinyl (vitamin A) esters. Normal stellate cells display several patterns of intermediate filaments expression (e.g., desmin, vimentin, and/or glial fibrillary acidic protein) suggesting that there are subpopulations within this parental cell type. In the normal liver, stellate cells participate in retinoid storage, vasoregulation through endothelial cell interactions, extracellular matrix homeostasis, drug detoxification, immunotolerance, and possibly the preservation of hepatocyte mass through secretion of mitogens including hepatocyte growth factor. During liver injury, stellate cells activate into alpha smooth muscle actin-expressing contractile myofibroblasts, which contribute to vascular distortion and increased vascular resistance, thereby promoting portal hypertension. Other features of stellate cell activation include mitogen-mediated proliferation, increased fibrogenesis driven by connective tissue growth factor, and transforming growth factor beta 1, amplified inflammation and immunoregulation, and altered matrix degradation. Evolving areas of interest in stellate cell biology seek to understand mechanisms of their clearance during fibrosis resolution by either apoptosis, senescence, or reversion, and their contribution to hepatic stem cell amplification, regeneration, and hepatocellular cancer. © 2013 American Physiological Society. Compr Physiol 3:1473-1492, 2013.
Article
Among adult patients with liver disease, the ability to identify those most likely to have cirrhosis noninvasively is challenging. To identify simple clinical indicators that can exclude or detect cirrhosis in adults with known or suspected liver disease. We searched MEDLINE and EMBASE (1966 to December 2011) and reference lists from retrieved articles, previous reviews, and physical examination textbooks. We retained 86 studies of adequate quality that evaluated the accuracy of clinical findings for identifying histologically proven cirrhosis. Two authors independently abstracted data (sensitivity, specificity, and likelihood ratios [LRs]) and assessed methodological quality. Random-effects meta-analyses were used to calculate summary LRs across studies. Among the 86 studies, 19,533 patients were included in this meta-analysis, among whom 4725 had biopsy-proven cirrhosis (prevalence rate, 24%; 95% CI, 20%-28%). Many physical examination and simple laboratory tests increase the likelihood of cirrhosis, though the presence of ascites (LR, 7.2; 95% CI, 2.9-12), a platelet count <160 x 10(3)/μL (LR, 6.3; 95% CI, 4.3-8.3), spider nevi (LR, 4.3; 95% CI 2.4-6.2), or a combination of simple laboratory tests with the Bonacini cirrhosis discriminant score >7 (LR, 9.4; 95% CI, 2.6-37) are the most frequently studied, reliable, and informative results. For lowering the likelihood of cirrhosis, the most useful findings are a Lok index <0.2 (a score created from the platelet count, serum aspartate aminotransferase and alanine aminotransferase, and prothrombin international normalized ratio; LR, 0.09; 95% CI, 0.03-0.31); a platelet count ≥160 x 10(3)/μL (LR, 0.29; 95% CI, 0.20-0.39); or the absence of hepatomegaly (LR, 0.37; 95% CI, 0.24-0.51). The overall impression of the clinician was not as informative as the individual findings or laboratory combinations. For identifying cirrhosis, the presence of a variety of clinical findings or abnormalities in a combination of simple laboratory tests that reflect the underlying pathophysiology increase its likelihood. To exclude cirrhosis, combinations of normal laboratory findings are most useful.
Article
Severe congestive heart failure is associated with two distinct forms of liver dysfunction: jaundice that is related to passive congestion and acute hepatocellular necrosis that is caused by impaired perfusion. Cardiac cirrhosis (fibrosis) may result from prolonged recurrent congestive heart failure. Ischemic hepatitis (shock liver) usually manifests as asymptomatic elevation of the serum aminotransferase levels after an episode of hypotension, although the clinical presentation may mimic that of acute viral hepatitis. In most cases, ischemic hepatitis is of little clinical consequence and is self-limited. Acute liver failure may occur in patients with preexisting cirrhosis, severe chronic heart failure, or sustained hepatic ischemia.
Article
Liver transplantation and antiviral treatments for hepatitis have improved the outlook for many patients with liver disease. For patients with cirrhosis, new developments herald targeted treatments.
Article
PBC is an old disease first described in 1851. It's predilection for women and its association with other autoimmune diseases suggests an immune based pathogenesis, but epidemiologic studies indicate that genetic and environmental factors play a role in the pathogenesis of PBC. The serologic hallmark for PBC, namely the antimitochondrial antibody, was first identified in 1965 and remains the most sensitive and specific hallmark for this disease. When first described, primary biliary cirrhosis was universally fatal but asymptomatic cases now represent more than 60% of cases diagnosed, less than half of whom will die of their liver disease. No specific therapy that effectively stops or reverses disease progression has been identified, thus it behoves investigators to aggressively pursue identification of the etiology of PBC.
Pathogenesis of Hepatic Fibrosis. Tadataka Yamada. Textbook of Gastroenterology. 4 th Edition
  • B David
  • R A Rippe
David B, Rippe R A. Pathogenesis of Hepatic Fibrosis. Tadataka Yamada. Textbook of Gastroenterology. 4 th Edition. Lippincott Williams & Wilkins, Philadelphia, 2003.
Chapter 14: Liver Disease. Pathophysiology of disease: an introduction to clinical medicine 6 th edition
  • S J Mcphee
  • D Gary
McPhee S J, Gary D. Chapter 14: Liver Disease. Pathophysiology of disease: an introduction to clinical medicine 6 th edition. McGraw-Hill Medical, New York, 2010.